Stock Notes

Zydus Wellness

Every Finvezto stock note on Zydus Wellness, dated and newest first. Coverage spans fmcg.

1 note and counting
22 Oct 2026
FSSAI issued notices to Nestlé India and Zydus Wellness seeking scientific proof for claims on infant formula and Complan.
Complan's '2X Faster Growth' and immunity and digestibility claims on Nestlé's NAN and Lactogen are at issue; both companies say the claims are backed by science.
Mentioned alongside
Nestlé India
Finvezto Membership

Get the research behind the notes

Stock notes are the free daily layer. The membership carries the full Flexi-Wealth system: an ETF core portfolio with monthly rebalancing signals, fifteen quality-momentum stocks with exact weightages every month, options income and hedging recommendations, and the institutional data toolkit. One flat membership covers everything.

Become a Member Read free sample research →

Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630. Stock notes are market commentary for general information and education. They are not investment advice, not a recommendation to buy or sell, and do not account for any individual's financial situation. Investment in securities is subject to market risks. Please read all related documents carefully before investing. Past performance is not a guarantee of future results.